13 June 2019
FDA Grant Breakthrough Designation for ResistancePlus® GC
The U.S. Food and Drug Administration (FDA) has granted Breakthrough Designation for ResistancePlus® GC - expediting the path towards clearance....
14 May 2019
PlexPCR® RespiVirus receives TGA clearance for sale in Australia
PlexPCR® RespiVirus received clearance from the Australian Therapeutic Goods Administration (TGA), bringing much needed workflow advantages in time for the...
3 May 2019
Study gauges impact of genotyping on gonorrhea treatment
Dr. Klausner, a clinical professor at UCLA, shares the details of his work with genotypic testing for ciprofloxacin susceptibility in...
24 April 2019
SpeeDx Close Series A Fundraising With Support From U.S. Venture Firm
SpeeDx announced further series A funding received by new investor partners, Northpond Ventures, LP – a U.S.-based, formative stage venture...
16 April 2019
SpeeDx and Cepheid announce test partnership
SpeeDx Pty, Ltd. announced an agreement with Cepheid to manufacture their market-leading ResistancePlus® tests for use on the GeneXpert System....
15 April 2019
SpeeDx trusted assay partner for Cepheid FleXible for the GeneXpert program
ResistancePlus® MG will be the first test available through Cepheid's FleXible cartridge program. This partnership will increase access for clinicians...
